About

Keith L. Duffy, MD, is a highly skilled dermatologist specializing in dermatology, high risk skin cancer, Mohs surgery, non-melanoma skin cancers, melanoma surgery, and cutaneous oncology. He is affiliated with multiple clinical locations including Midvalley Health Center, Veterans Administration Medical Center, Huntsman Cancer Institute, and University of Utah Hospital. Dr. Duffy is recognized for his meticulous surgical techniques, expertise in Mohs procedures, and compassionate patient care. His reputation is supported by a patient rating of 4.9 out of 5, reflecting his professionalism, kindness, and ability to explain complex medical information in understandable terms. He is highly regarded for his thoroughness, attention to detail, and dedication to providing personalized treatment, making him a trusted provider in skin cancer treatment and reconstructive care.

Research topics

• Medicine
• Internal medicine
• Family medicine
• Computer Science
• Surgery
• Biology
• Medical education
• Cell biology
• Cancer research
• Pharmacology
• Chemistry

Selected publications

• Supplemental Data from Assessing <i>MC1R</i> Variants in Lentigo Maligna Melanoma within the Utah Population

  2025-07-28

  preprintOpen access

  <p>Sanger sequencing data for each sample</p>

  PublisherDOI

• Supplementary Table 1 from Assessing <i>MC1R</i> Variants in Lentigo Maligna Melanoma within the Utah Population

  2025-07-28

  supplementary-materialsOpen access

  <p>Table of dbSNP allele frequencies</p>

  PublisherDOI

• Figure 2 from Assessing <i>MC1R</i> Variants in Lentigo Maligna Melanoma within the Utah Population

  2025-07-28

  preprintOpen access

  <p>Specific <i>MC1R</i> genotypes confer an increased risk of developing LM/LMM. The heatmaps display the percentage frequencies of <i>MC1R</i> genotypes within two cohorts: (<b>A</b>) Mohs LM/LMM cohort and (<b>B</b>) the Utah reference group. The heatmaps are color-coded to reflect genotype percentages, with red indicating higher frequencies and green indicating lower frequencies. This comparison highlights the differential distribution of <i>MC1R</i> genotypes between patients with LM/LMM and the Utah reference group. * denotes samples for which we calculated an OR compared with WT or heterozygous/homozygous genotypes.</p>

  PublisherDOI

• Recurrence Rates of Keratinocyte Carcinoma Treated With Curettage Alone: A Retrospective Cohort and Interview Study

  Dermatologic Surgery · 2025-06-13 · 1 citations

  article

  BACKGROUND: In the treatment of keratinocyte carcinoma, curettage alone has been described as a simpler, less expensive, and quicker method than electrodessication and curettage; however, there are limited studies examining recurrence rates for such lesions. OBJECTIVE: To investigate the 5-year recurrence rates of keratinocyte carcinoma treated with curettage alone and compare these results to previously reported recurrence rates for electrodessication and curettage. PATIENTS AND METHODS: A retrospective cohort and interview study determined 5-year recurrence rates for 1,853 total lesions treated with curettage alone using chart review data and patient phone calls. RESULTS: This study yielded a per-protocol 5-year recurrence rate of 2.41% for BCCs, 4.52% for SCCs, and an average of 3.71% across both types of keratinocyte carcinoma. Lesions on the head and neck displayed a significantly greater recurrence rate of 7.18% when treated with curettage alone. CONCLUSION: Curettage alone provides comparable efficacy in curing keratinocyte carcinoma when compared with electrodessication and curettage.

  PublisherDOI

• Data from Assessing <i>MC1R</i> Variants in Lentigo Maligna Melanoma within the Utah Population

  2025-07-28

  preprintOpen access

  <div>Abstract<p>Lentigo maligna (LM) and lentigo maligna melanoma (LMM) arise from chronically sun-damaged skin. LM/LMM incidence continues to increase, particularly in Utah, where melanoma rates are twice the national average. The melanocortin-1 receptor (<i>MC1R</i>) has been studied in melanocyte pigmentation and DNA repair but has yet to be thoroughly investigated in LM/LMM. We investigated allele and genotype frequencies of germline <i>MC1R</i> variants among 175 Utah patients diagnosed with LM/LMM and 402 Utah reference individuals. The comparative analysis demonstrated an increased frequency of the D294H allele (0.046; <i>P</i> = 0.0042) and a decreased frequency of the V60L allele (0.074; <i>P</i> = 0.034) in patients with LM/LMM. The LM/LMM group demonstrated a higher OR compared with the Utah reference group associated with R151C homozygosity compared with heterozygous R151C [OR = 5.6; 95% confidence interval (CI), 0.98–32; <i>P</i> = 0.052] and R151C homozygosity compared with wild type (OR = 5.7; 95% CI, 1.1–30; <i>P</i> = 0.042). D294H heterozygosity was strongly associated with LM/LMM (OR = 3.8; 95% CI, 1.3–11; <i>P</i> = 0.014). Conversely, V60L heterozygosity was less strongly associated with LM/LMM (OR = 0.52; 95% CI, 0.26–1.1; <i>P</i> = 0.072). Stratified analyses showed no significant differences in age or gender across the key <i>MC1R</i> variants studied. These data highlight significant differences in <i>MC1R</i> allele frequencies in patients with LM/LMM, demonstrating that D294H is associated with increased LM/LMM risk, whereas the V60L variant is inversely associated with risk. This study provides the first comprehensive analysis of specific high-risk <i>MC1R</i> variants in patients with LM/LMM in Utah.</p>Significance:<p>Our study is the first comprehensive analysis of <i>MC1R</i> germline variants in patients with LM/LMM in Utah, a region with an exceptionally high melanoma incidence. We draw new risk associations in LM/LMM, identifying an increased risk with the D294H and R151C variants. We also describe a novel inverse association for V60L, warranting further investigation. This study contributes to improved targeted risk stratification and an increased understanding of an understudied melanoma subtype.</p></div>

  PublisherDOI

• Supplementary Figure 1 from Assessing <i>MC1R</i> Variants in Lentigo Maligna Melanoma within the Utah Population

  2025-07-28

  preprintOpen access

  <p>Figure of age and gender distribution for key MC1R variants.</p>

  PublisherOA PDFDOI

• Table 1 from Assessing <i>MC1R</i> Variants in Lentigo Maligna Melanoma within the Utah Population

  2025-07-28

  preprintOpen access

  <p>Key demographic characteristics of patients with LM/LMM in the study (<i>n</i> = 175)</p>

  PublisherDOI

• Supplementary Table 2 from Assessing <i>MC1R</i> Variants in Lentigo Maligna Melanoma within the Utah Population

  2025-07-28

  supplementary-materialsOpen access

  <p>Table of the Utah reference group data</p>

  PublisherDOI

• Assessing <i>MC1R</i> Variants in Lentigo Maligna Melanoma within the Utah Population

  Cancer Research Communications · 2025-07-01

  articleOpen access

  Lentigo maligna (LM) and lentigo maligna melanoma (LMM) arise from chronically sun-damaged skin. LM/LMM incidence continues to increase, particularly in Utah, where melanoma rates are twice the national average. The melanocortin-1 receptor (MC1R) has been studied in melanocyte pigmentation and DNA repair but has yet to be thoroughly investigated in LM/LMM. We investigated allele and genotype frequencies of germline MC1R variants among 175 Utah patients diagnosed with LM/LMM and 402 Utah reference individuals. The comparative analysis demonstrated an increased frequency of the D294H allele (0.046; P = 0.0042) and a decreased frequency of the V60L allele (0.074; P = 0.034) in patients with LM/LMM. The LM/LMM group demonstrated a higher OR compared with the Utah reference group associated with R151C homozygosity compared with heterozygous R151C [OR = 5.6; 95% confidence interval (CI), 0.98-32; P = 0.052] and R151C homozygosity compared with wild type (OR = 5.7; 95% CI, 1.1-30; P = 0.042). D294H heterozygosity was strongly associated with LM/LMM (OR = 3.8; 95% CI, 1.3-11; P = 0.014). Conversely, V60L heterozygosity was less strongly associated with LM/LMM (OR = 0.52; 95% CI, 0.26-1.1; P = 0.072). Stratified analyses showed no significant differences in age or gender across the key MC1R variants studied. These data highlight significant differences in MC1R allele frequencies in patients with LM/LMM, demonstrating that D294H is associated with increased LM/LMM risk, whereas the V60L variant is inversely associated with risk. This study provides the first comprehensive analysis of specific high-risk MC1R variants in patients with LM/LMM in Utah. SIGNIFICANCE: Our study is the first comprehensive analysis of MC1R germline variants in patients with LM/LMM in Utah, a region with an exceptionally high melanoma incidence. We draw new risk associations in LM/LMM, identifying an increased risk with the D294H and R151C variants. We also describe a novel inverse association for V60L, warranting further investigation. This study contributes to improved targeted risk stratification and an increased understanding of an understudied melanoma subtype.

  PublisherOA PDFDOI

• Assessing Real-World Utilization/Performance of Salivary Gland Biopsy in Diagnosis of Sjögren Disease: Impact of Overweighting Without Objective Glandular Testing

  JCR Journal of Clinical Rheumatology · 2025-11-03

  articleCorresponding

  OBJECTIVE: Retrospective cohort study assessing real-world use patterns and test properties of labial salivary gland biopsy (LSGBx) for diagnosing Sjögren's disease (SjD). METHODS: We retrieved 89 LSGBx samples from our dermatopathology archive and obtained 23 cadaveric LSGBx samples without known autoimmune diseases for control. SjD cases included 15 seropositive Sjögren's disease (spSjD), 34 seronegative Sjögren's disease (snSjD), and 40 not SjD. All slides were de-identified and presented in random order to a blinded dermatopathologist and oral pathologist to review and score all samples according to established criteria. Patient demographics and clinical information were obtained via chart review. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of LSGBx were calculated, and odds of a SjD diagnosis after a positive LSGBx was assessed with logistic regression. RESULTS: LSGBx supported SjD in 73.3% of spSjD, 73.5% of snSjD, and 55.0% of notSjD cases, and 21.7% of cadaveric specimens. Sensitivity for SjD (spSjD + snSjD) was 73.5%, specificity was 45.0%, PPV was 62.1%, and NPV was 58.1%. A positive LSGBx increased the odds of SjD (OR=2.27, 95% CI: 0.93-5.51). The odds were similar and non-significant for spSjD and snSjD. Cadaveric specimens had lower LSGBx positivity rates compared to notSjD cases (OR=0.24, 95% CI: 0.07-0.77). Objective measures of eye dryness (14/89 cases) or oral dryness (0/89) were infrequently assessed. CONCLUSION: The predictive value of LSGBx for SjD is limited. The lack of objective clinical data in this cohort suggests that LSGBx is often heavily weighted for diagnosis, but these data question that approach.

  PublisherDOI

Frequent coauthors

• Glen M. Bowen

  University of Utah

  26 shared

• Allie H. Grossmann

  University of Utah

  26 shared

• David A. Kircher

  24 shared

• Michelle C. Mendoza

  University of California, San Diego

  24 shared

• Stephanie N. Angel

  24 shared

• Martin McMahon

  24 shared

• Kirby A. Trombetti

  Midwestern University

  24 shared

• Christopher M. Stehn

  24 shared

Education

• B.S.

  Boston College

• M.D.

  SUNY Upstate